Why Hims & Hers Health Fell by Nearly 11% Today
The stock of specialty telemedicine company Hims & Hers (NYSE: HIMS) took a big hit on Monday, cratering by 10.8%. It seems an analyst's modest price chop led to the investor sell-off.
Early that morning, Credit Suisse prognosticator Jailendra Singh updated his price target on the stock, lowering it from $16 per share to $14. While doing so, however, he maintained his outperform (i.e., buy) recommendation.
That's still a very bullish outlook on Hims & Hers' potential. Even though it's been reduced, that price target is still nearly double the stock's current level.
Source Fool.com
